This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

November 2-5, 2020
Now Delivered Digitally,
in US Pacific Standard Time (PST)

LOOKING BEYOND ANTIBODIES TO TRANSFORM PROMISING NOVEL MOLECULES INTO NEXT GENERATION MEDICINE

Advance your innovative biologics with cutting-edge engineering, design and conjugates, progress to the clinic and achieve top quality products with analytics and successful workflows.

REDEFINING YOUR LEARNING EXPERIENCE

In light of the current global climate, it is more important than ever for the protein therapeutics and bioconjugates communities to connect with one another, strategize and share ideas – All in a safe, responsible way.

With our dedication to address the most pressing issues, our Next Generation Protein Therapeutics & Bioconjugates Summit, now taking place November 2-5, 2020, has undergone a timely transformation, moving to an all-digital format and offering attendees the ability to participate in virtual content, exhibits and networking opportunities.


UNIQUE BENEFITS OF THIS ALL-VIRTUAL EVENT
UNIQUE BENEFITS OF THIS ALL-VIRTUAL EVENT
  • Customizable agenda with access to expanded session offerings
  • Convenient session scheduling for increased productivity
  • On-demand access to content and topic resources
  • Interactive presentations/panels for reinforced learning
  • Pointed problem-solving and solution sourcing
  • Broader industry benchmarking and post-event analytics/insights
  • Elevated and direct access to thought leaders and experts
POWER OF NETWORKING
POWER OF NETWORKING

Who’s Who?
Attendee and company profiles provide insight into the delegation and sponsoring organizations
Advanced search capabilities to identify opportunities and potential partners

When and How to Connect?

Sophisticated and seamless scheduling tools to establish meeting tim


DIGITAL CAPABILITIES AND FEATURES
DIGITAL CAPABILITIES AND FEATURES
  • Access to Virtual Environment
  • Audience Q&A
  • Live Polling
  • Expert-Led Problem-Solving
  • Virtual Networking and Partnering
COMPREHENSIVE CONTENT AND DYNAMIC FEATURES
COMPREHENSIVE CONTENT AND DYNAMIC FEATURES
  • 30+ Pre-recorded Presentations that will become on-demand at the end of each day
  • Over 6 Hours of Live Speaker Q&A Sessions
  • Networking with Industry Colleagues and Counterparts

LIVE PRESENTATIONS AND Q&A SESSIONS

Throughout the week there will be live panel discussions and content streamed. Attendees can view by going into the "Live" section of the portal at the designated time listed in US Pacific Standard Time zone (PST). Polling and Q&A will be live through various sessions and sessions will be recorded for viewing at a later time if desired.


KEYNOTE: Immune-empowered Antibodies and Bispecific Molecules for Oncology: Bench to Bedside
KEYNOTE: Immune-empowered Antibodies and Bispecific Molecules for Oncology: Bench to Bedside

Paul Moore, Ph.D., Vice President Immunology & Cell Biology, Macrogenics

KEYNOTE: Cancer Wars: The Rise of Antibody Drug Bioconjugates
KEYNOTE: Cancer Wars: The Rise of Antibody Drug Bioconjugates

Rakesh Dixit, President & CEO, Bionavigen

Conjugated Proteins: A Rational Design for Mitigating Clearance Mechanisms and Altering Biodistribution
Conjugated Proteins: A Rational Design for Mitigating Clearance Mechanisms and Altering Biodistribution

Mary Bossard, Principal Fellow, Nektar Therapeutics


Engineering design and Lessons Learned from a Novel Bispecific Receptor-mAb Fusion
Engineering design and Lessons Learned from a Novel Bispecific Receptor-mAb Fusion

Bernhard Sielaff, Principal Research Scientist II, Abbvie

XTENylated Protease Activated T cell engagers: XPATS - A novel format to mitigate the on-target, off-tumor problem
XTENylated Protease Activated T cell engagers: XPATS - A novel format to mitigate the on-target, off-tumor problem

Volker Schellenberger, CTO, Amunix

New Technologies To Advance Bispecific Antibodies From Research Into Early or Clinical Development
New Technologies To Advance Bispecific Antibodies From Research Into Early or Clinical Development

Christoph Spiess, Principal Scientist, Antibody Engineering, Genentech


KEYNOTE: An Overview of Daichi Sankyo's ADCs: Preclinical and Clinical updates on DXd-based ADCs
KEYNOTE: An Overview of Daichi Sankyo's ADCs: Preclinical and Clinical updates on DXd-based ADCs

Jun Hasegawa, Senior Researcher, Daichii Sankyo

KEYNOTE: Update on applications of CrossMab Technology for the Generation of Bispecific Antibodies for Cancer Immunotheray
KEYNOTE: Update on applications of CrossMab Technology for the Generation of Bispecific Antibodies for Cancer Immunotheray

Christian Klein, Head Oncology Programs, Roche Innovation

KEYNOTE: Optimising ADCs Through Choice of Antibody, Site, Linker and Payload
KEYNOTE: Optimising ADCs Through Choice of Antibody, Site, Linker and Payload

Thomas Pillow, Senior Scientist, Genentech


KEYNOTE: Experimental and Computational Methods For Generating and Engineering Antibodies with Drug-like Properties
KEYNOTE: Experimental and Computational Methods For Generating and Engineering Antibodies with Drug-like Properties

Peter Tessier, Albert M Mattocks, Professor of Pharmaceutical Sciences, University of Michigan

KEYNOTE: Cancer Therapy Using Antibody-Cytokine Fusion Proteins
KEYNOTE: Cancer Therapy Using Antibody-Cytokine Fusion Proteins

Dari Neri, Professor, ETH

KEYNOTE: Centryn Conjugates for Selective Targeting of Functional Payloads
KEYNOTE: Centryn Conjugates for Selective Targeting of Functional Payloads

Steven Nadler, Vice President of Research, Aro Biotherapeutics


Oligonucleotide Therapeutics: Now on Target with Antibody Conjugates
Oligonucleotide Therapeutics: Now on Target with Antibody Conjugates

Art Levin, CSO, Avidity Biosciences

Balancing Increased Half-Life & Size of Protein Scaffolds: Preclinical to Clinical translation
Balancing Increased Half-Life & Size of Protein Scaffolds: Preclinical to Clinical translation

Frefrik Frejd, CSO, Affibody AB

Antagonistic antibodies and KO mice used to establish a key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis
Antagonistic antibodies and KO mice used to establish a key role for IL-13 signaling via the type 2 IL-4 receptor in experimental atopic dermatitis

Itai Benhar, Head of Antibody Engineering Lab, Tel-Aviv University

IN-DEPTH ON-DEMAND CONTENT — WHAT YOU WANT. WHEN YOU WANT IT

On-Demand content is available anytime, to accommodate your needs and schedule.


SBT6050, a HER2-Directed TLR8 ImmunoTAC™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity
SBT6050, a HER2-Directed TLR8 ImmunoTAC™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity

Sean W. Smith, Senior Director, Chemistry, Silverback Therapeutics

Site Specific Lysine and Cysteine based conjugation
Site Specific Lysine and Cysteine based conjugation

Barbara Bernardim, Professor, Cambridge University

CM-09, a Novel Antibody-Drug-Conjugate to TRA-1-60, a Cellular Reprogrammed Target in Metastatic Gastric and Pancreatic Cancers
CM-09, a Novel Antibody-Drug-Conjugate to TRA-1-60, a Cellular Reprogrammed Target in Metastatic Gastric and Pancreatic Cancers

Michael Schopperle, Chief Executive Officer, CureMeta

Present a Scientific Poster

Consider presenting a poster at this virtual event to derive more value from attending. Share your research with your peers and learn from other posters as well. Many attendees tell us that being selected for a poster presentation helps to facilitate their company approval process to attend the event. Submit your poster abstract online today using the form below.

Deadline: Monday, October 12, 2020

Please note that all poster presenters must be registered attendees for the main conference. 

Exclusive Whitepaper Downloads


Use of Next Generation Protein Therapeutics Over Traditional Monoclonal Antibodies and Different Approaches
Use of Next Generation Protein Therapeutics Over Traditional Monoclonal Antibodies and Different Approaches

According to BIS Research and Research and Markets the worldwide biologics drug discovery market is predicted to increase from USD $8.1 billion in 2015 to USD $22.7 billion by 2025 (Figure 1). The biologics discovery growth rate is predicted to be faster than in the dominant small molecule discovery sector. Monoclonal antibodies are expected to make up just under half of the biologics discovery market in 2025. Engineered or recombinant proteins such as next generation protein therapeutics are expected to contribute 3 billion to the market in 2025.

The dominance of monoclonal antibodies (mAbs) are due to several factors including their efficacy brought about by their high specificity allowing selective targeting

Download this Whitepaper
Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies
Creating New Pathways for the Development, Translation, and Delivery of Immunotherapies

The last decade has seen substantial growth of immunotherapy treatments for cancer. The new immunotherapies have produced exciting results in terms of response rates to treatment for certain cancers, such as melanoma, which have been refractory to treatment, once substantial metastasis has occurred. The US Food and Drug Administration (FDA) has approved several antibodies against immune checkpoint inhibitors based on the encouraging results in clinical trials. Other types of immune therapies are also being developed which may also be useful in the treatment of cancer.

Download this Whitepaper

CONNECT WITH KEY BUYERS AT NEXT GEN SUMMIT 2020

Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.  

Contact Kristen Schott: +1 857 504 6685 or KSchott@informaconnectls.com

Get the latest event updates

Sign up to get the latest event updates and information.